NOV 15, 2018 6:00 AM CET

HDV, the most severe form of viral hepatitis. What you need to know about it

Sponsored by: DiaSorin
C.E. Credits: P.A.C.E. CE Florida CE
  • Associate Professor of Virology at the Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Italy
      Valentina Svicher is an Associate Professor of Virology at the Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata". She got a degree cum laude in Biological Sciences in 2001 and a PhD in Microbiology and Immunology in 2006. Her research interests and expertise are focused on mechanisms underlying pathogenesis and response to therapy in the setting of chronic viral infections with particular attention on hepatitis B and D virus.
      She is author of more than 90 full papers in peer-reviewed journals, and more than 250 papers presented at numerous National and International Conferences. She received several awards such as "GB Rossi" Scientific Prize 2009, "Readfiles" Scientific Award 2008 and the Scientific Award "Infection Lab 2016" for the best scientific publications or projects in the infectivology field.
      She collaborates with many nationally and internationally recognized scientific researchers through grants from the Italian National Institute of Health, the Ministry of University and Scientific Research, the European Community and Industrial Companies.
      She is member of the Board of the Scientific Society "European Society for Antiviral Research (ESAR); Member of the HCV Italian Resistance Network Study Group; Member of the European HepCare group; Member of the Italian Study Group on the treatment and prophylaxis of HBV in the haematological patients.
    • Head of the Hepatitis Unit at the Spanish National Center of Microbiology, Istituto de Salud Carlos III Madrid, Spain
        Medical Doctor and PhD, has more than 20 years of experience in the Virology field, being the Head of the Hepatitis Unit at the Spanish National Center of Microbiology since 2010. Her responsibilities extent to hepatitis viruses reference and surveillance activities, including confirmation of diagnosis and characterization. Currently she participates as an expert in ECDC hepatitis B & C group and in ECDC hepatitis E group.

      DATE: November 15, 2018
      TIME: 06:00am PST, 09:00am EST, 3:00pm CET
      Part 1 - Presented by Valentina Svicher
      Hepatitis Delta Virus: insights and emerging concepts into a peculiar pathogen
      Hepatitis D virus (HDV) is a unique RNA virus that requires the hepatitis B surface antigen (HBsAg) to infect the hepatocytes. Chronic Hepatitis D is recognized as the most severe form of viral hepatitis, leading to accelerated progression of cirrhosis and hepatocellular carcinoma and a high mortality rate. HDV infection affects an estimated 15–20 million individuals, is spread worldwide and is endemic in some regions. Moreover, HDV prevalence is increasing in many countries as a consequence of immigration from highly endemic geographic areas.
      Despite the severity of hepatitis D, screening and treatment has been often neglected in part due to the lack of an effective therapy.  Indeed, interferon alpha is the only anti-HDV drug approved for the treatment of chronic hepatitis D, even if its efficacy is limited and side effects can be severe. Future therapeutic options are under investigation targeting HDV entry, HBsAg secretion, and viral assembly. This webinar will summarize current knowledge on virological and epidemiological aspects of HDV infection with particular attention of categories of individuals in which HDV testing should be prioritized. It also provides an overview on the upcoming treatment options against this virus.
      Learning Objectives:
      • Discuss epidemiological and virological aspects of HDV infection
      • Identify categories of individuals at risk of acquiring HDV infection
      • Describe current and future HDV treatments
      Part 2 - Presented by Ana Avellon
      HDV infection: how and when to diagnose a forgotten disease 
      Although the most aggressive infectious liver disease, hepatitis delta virus (HDV) infection may be underdiagnosed both for the unawareness or the unavailability of accurate diagnostic methods. Any hepatitis B virus (HBV) infected patient is susceptible to HDV infection for life and consequently searching for HDV should be included in HBV infected patient monitoring guidelines. Periodically detection of HDV antibody and viral RNA in HBV infected patients can early diagnose HDV and may impact the progress of the liver disease.
      Learning Objectives:
      • How to diagnose HDV: methods and interpretation of results
      • When to ask for HDV diagnosis: guidelines review

      Show Resources
      Show Resources
      • See more
      Connect with us